Cingulate Inc.
Cingulate Inc. is a clinical-stage pharmaceutical company developing differentiated prescription therapies, with its lead program CTx-1301 aimed at ADHD. The company is focused on advancing its pipeline through clinical development, regulatory filing, and eventual commercialization via partnerships or outsourced sales infrastructure.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical development, manufacturing, and regulatory work for CTx-1301 and related pipeline assets.
Evaluation of new products, product candidates, and acquisitions to broaden the portfolio.
Potential licensing and fee-for-service commercialization support for approved products.
Externally funded clinical and manufacturing work, including CTx-2103 support.
Customers
Cingulate does not yet sell commercial products, so its near-term counterparties are primarily clinical research organizations, manufacturers, regulators, and potential licensing partners. If approved, its end customers would be physicians, patients, and payers in the ADHD market, with commercialization potentially handled through partners rather than a large internal sales force.
Companies that may license CTx-1301 in the U.S. or internationally to commercialize the asset.
CROs, investigators, and manufacturers that provide trial execution, supply, and testing services.
FDA and comparable authorities that review the NDA and determine approval timing.
Physicians and patients who would use the product if approved, driving eventual product demand.
Strategy
Cingulate’s strategy is to complete development of CTx-1301, file the NDA, and secure a pharmaceutical partner or outsourced commercialization model. It is also trying to broaden the pipeline through in-licensing, acquisitions, and grant- or partner-supported development to reduce dependence on a single asset.
Regulatory submission is the key milestone needed to move the lead asset toward approval and value creation.
A partner can provide commercialization reach and reduce the need for Cingulate to build costly sales infrastructure.
The company needs additional capital to continue development and support launch activities if approval is obtained.
Adding assets through in-licensing or acquisition can diversify risk beyond a single lead program.
Geography
Cingulate is headquartered in the United States and its current development, regulatory, and commercialization planning is centered there. The company also states it may seek international licensing for CTx-1301, but it has not disclosed meaningful country revenue because it has not generated product sales.
Risks
Cingulate is a pre-revenue clinical-stage company, so its business depends on successful trials, regulatory approval, and access to capital. The company also faces execution risk around manufacturing, commercialization outsourcing, and partner selection, while broader pharmaceutical risks include patent disputes, FDA delays, and inability to retain key personnel.
- Going-concern and financing riskImpact: Critical
The company has no product revenue and expects to need additional capital to fund operations and commercialization.
Exposure: Cash runway into fourth quarter 2025 under current plan
- Clinical and regulatory failure riskImpact: HighLikelihood: High
CTx-1301 and other candidates may not achieve successful trial outcomes or FDA approval.
Exposure: Lead asset NDA timing and approval pathway
- Commercialization execution riskImpact: HighLikelihood: Low
The company may rely on partners or outsourced providers for marketing, sales, market access, and distribution.
Exposure: Indegene MSA and future licensing arrangements
- Manufacturing and supply chain riskImpact: MediumLikelihood: High
Clinical supply and commercial-scale manufacturing timing can affect trial progress and launch readiness.
Exposure: CTx-1301 and CTx-2103 development
- Key personnel retention riskImpact: MediumLikelihood: High
A small development-stage company depends heavily on a limited management and scientific team.
Exposure: Management and R&D execution
Accounting
Judgemental itemsExternal development costs are recognized based on vendor progress, which requires judgment and can shift quarterly expense timing.
Impact: Affects operating loss comparability quarter to quarter
Management states substantial doubt about the company’s ability to continue as a going concern without additional capital.
Impact: Important for liquidity and financial statement interpretation
The $3 million grant for CTx-2103 and contingent royalty payments create specific funding and future obligation considerations.
Impact: Affects cash flow, liabilities, and future commercialization economics
Any future partnership or licensing deal could create upfront, milestone, or service revenue with complex timing.
Impact: Could materially change reported revenue once commercialization begins
Similar listed companies
Publicly listed companies with a comparable business focus.
Minerva Neurosciences, Inc.
NERV · Pharmaceutical Preparations
Actuate Therapeutics, Inc
ACTU · Pharmaceutical Preparations
CTT Pharmaceutical Holdings, Inc.
CTTH · Pharmaceutical Preparations
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Last updated: 24/09/2026